Cognito Therapeutics patents gamma sensory stimulation technology that reduces white atrophy
The developers claim that the patentedGamma sensory stimulation at 40 Hz for six months reduces white matter atrophy in patients with Alzheimer's disease and may also protect axons and possibly prevent damage to myelin and oligodendrocytes.
Cognito Therapeutics plans to start trials to confirm the device's clinical effectiveness as early as this year.